When does Pharming (PHARM.AS) report Q4 earnings?

Pharming Group (PHARM.AS stock) is scheduled to report Q4 results on **12 March 2026**. Market reaction will hinge on Ruconest sales, guidance and partnership milestones.

What price targets does Meyka AI project for PHARM.AS stock?

Meyka AI's model projects **€1.54** for the quarter and **€2.05** for 12 months, versus the current price of **€1.375**. Forecasts are model-based and not guarantees.

What are the main risks for PHARM.AS stock after the earnings report?

Primary risks include weaker-than-expected Ruconest sales, negative pipeline readouts and valuation compression given PB **4.08** versus the Healthcare sector. Clinical or guidance misses would likely trigger sharper downside.

How liquid is PHARM.AS stock for intraday traders?

Intraday volume today is **4,047,188.00** with a 50-day average of **14,491,020.00**, giving relative volume near **0.85**. Liquidity is adequate but can widen around major news.

EU Stocks

PHARM.AS Pharming Group (EURONEXT) Q4 preview 11 Mar 2026: catalysts

ByDanny Kontos March 11, 2026March 11, 2026

PHARM.AS stock trades at €1.375 intraday as investors prepare for Pharming Group N.V.’s Q4 results due 12 March 2026; Ruconest sales and guidance will drive the move. We highlight revenue drivers, near-term guidance expectations and how upcoming data could shift the €969093340.00 market cap valuation on EURONEXT in Europe. This earnings spotlight focuses on metrics that matter for traders ahead of the report.